Zacks.com featured highlights include Murphy USA, DaVita, Microchip Technology and Cenovus Energy
Zacks Investment Research has identified four stocks—Murphy USA (MUSA), DaVita (DVA), Microchip Technology (MCHP), and Cenovus Energy (CVE)—that are currently trading near their 52-week highs and are expected to continue their upward momentum. The article details the strong near-term fundamental cases for each company, citing recent financial results, strategic initiatives, and analyst consensus estimate revisions. This analysis aims to help investors identify top-performing stocks with further growth potential, leveraging a momentum investing strategy.
DaVita stock (US23918K1088): Q4 2025 revenue beat and debt load stay in focus
DaVita Inc. reported strong Q4 2025 results with a 9.9% revenue increase to $3.62 billion and adjusted earnings of $3.40 per share, surpassing analyst estimates. Despite the positive operational performance driven by stable U.S. kidney-care demand, investors continue to monitor the company's significant debt load of $13.22 billion. DaVita's position as a key U.S. healthcare services provider means its stock is influenced more by domestic policy, reimbursement trends, and its financial structure than by broad macroeconomic factors.
Momentum Stocks to Buy and Sell: SMCI, DaVita, Insight Enterprises Analysis - News and Statistics
This article analyzes three momentum stocks, recommending one Buy and two Sells based on recent performance and underlying financial health. Super Micro Computer (SMCI) is rated a Buy due to significant revenue and EPS growth, while DaVita (DVA) and Insight Enterprises (NSIT) are flagged as Sells due to concerns over flat growth, increased capital intensity, and lagging EPS growth, despite recent stock price gains.
Beyond the Clinical: How Social Workers Drive Kidney Transplant Success
This article highlights the critical role of social workers in facilitating successful kidney transplants, emphasizing their contributions beyond clinical aspects. It details how social workers educate patients, address social barriers, and provide encouragement, using the personal experience of DaVita social worker Angela Laino as an example. The piece also discusses the systemic benefits of effective social work intervention, such as reduced wait times, improved survival rates, and optimized resource use within the healthcare system.
DaVita Honors Extraordinary Nurses With the 2026 DAISY Awards
DaVita has recognized 57 nephrology nurses with the 2026 DAISY Award for Extraordinary Nurses, celebrating their compassionate care and dedication to patients. This international award from the DAISY Foundation highlights nurses who provide outstanding service. DaVita emphasizes its commitment to supporting nursing excellence through education, training, and recognition programs, encouraging thriving careers for its clinical teammates.
DaVita stock (US23918K1088): solid Q1 2025 earnings keep dialysis specialist in focus
DaVita Inc. reported robust Q1 2025 earnings with increased revenue and adjusted earnings per share, leading to an upgraded full-year outlook. The company's performance benefited from higher treatment volumes and cost controls, despite ongoing healthcare sector challenges like wage inflation. DaVita, a major US dialysis provider, continues to focus on its core services, home dialysis, and value-based care, making it relevant for investors interested in chronic kidney disease treatment and healthcare policy.
DaVita Inc. Lifts Outlook After Q1 Earnings Beat
DaVita Inc. reported a strong Q1 earnings beat, leading to an optimistic outlook and raised full-year guidance for 2026. The company highlighted productivity gains, strong performance in integrated kidney care, and strategic investments in technology and AI as key drivers. Despite some near-term pressures like higher G&A and admission softness, DaVita expects sustained productivity-led growth with modestly improving volume and stable patient care costs.
DaVita Inc stock (US23804L1035): earnings, buyback and outlook after strong first quarter
DaVita Inc. started 2026 with strong first-quarter results, driven by higher treatment volumes and a favorable payer mix, leading to increased revenue and profitability. The company expanded its share buyback program and reiterated its strategic focus on integrated kidney care and efficient capital allocation. While operating in a stable demand environment, DaVita emphasizes careful monitoring of regulatory developments and industry competition due to the sector's policy-dependent nature.
DaVita Inc. stock outperforms competitors on strong trading day
DaVita Inc. (DVA) stock rose 1.16% to $196.87 on Wednesday, outperforming the broader market. This gain broke a two-day losing streak for the company's shares. The S&P 500 Index and Dow Jones Industrial Average also saw significant increases on the strong trading day.
AI shows promise as health systems invest in chronic disease tech
Health systems like Centerwell, Rush, and DaVita are investing in chronic disease technology, showing promise for AI in this sector. This comes as Nourish secures $100 million in funding to expand its network and invest further in AI. The article highlights the growing trend of healthcare providers leveraging technology for chronic disease management.
AI shows promise as health systems invest in chronic disease tech
Health systems like Centerwell, Rush, and DaVita are investing in AI and technology to improve chronic disease management. Memorial Hermann is using AI for patient guidance and capacity expansion, while Nourish recently secured $100M for network growth and AI investment, highlighting a growing trend in digital health solutions.
DaVita’s SWOT analysis: healthcare stock faces growth amid volatility
DaVita Inc. is experiencing significant earnings growth expectations, with 2026 EPS guidance representing a 33% increase. This optimistic outlook is fueled by strategic financial management, including share repurchases and debt refinancing, and favorable regulatory developments like a 2.2% Medicare rate update. Despite a Q3 2025 earnings miss that raised predictability concerns, analysts maintain a neutral stance, noting the stock's strong momentum and the company's efforts to drive shareholder value in the dialysis services sector.
DaVita stock (US23918K1088): Insider sale follows strong Q1 2026 earnings
DaVita (DVA) shares are in focus due to a combination of strong Q1 2026 earnings, which saw EPS of $2.87 surpassing forecasts, and a recent insider stock sale by Chief Compliance Officer James Hearty. This activity has drawn attention from investors interested in healthcare services. Despite the insider sale, the company's solid operating performance continues to be a key factor for its market activity, highlighting the interplay between financial results and sentiment-driven events.
DaVita Inc. stock underperforms Tuesday when compared to competitors
Shares of DaVita Inc. (DVA) fell by 2.46% to $194.61 on Tuesday, experiencing a second consecutive day of losses. This underperformance occurred during a generally down day for the stock market, with both the S&P 500 Index and Dow Jones Industrial Average also recording declines.
Best Value Stocks to Buy for May 19th
The article identifies three value stocks with a Zacks Rank #1 for investors to consider: Universal Insurance Holdings (UVE), Lifetime Brands (LCUT), and DaVita Inc. (DVA). Each company is highlighted for its strong value characteristics, including favorable price-to-earnings ratios compared to their respective industries, and recent increases in Zacks Consensus Estimates for their earnings. The article recommends these stocks for their potential as value investments.
DaVita stock (US23918K1088): solid Q1 2026, buyback boost and kidney care focus
DaVita reported strong Q1 2026 results with increased revenue and profit, driven by higher treatment volumes and an improved payer mix. The company also expanded its share repurchase program, demonstrating a shareholder-focused capital allocation strategy. DaVita is investing in home dialysis and value-based care initiatives to adapt to evolving US healthcare policies, while navigating regulatory and reimbursement challenges inherent in the kidney care sector.
DaVita Sets Bold 2030 Community Care Commitments After Exceeding Prior Five-Year ESG Goals
DaVita has announced its ambitious 2030 Community Care commitments, focusing on improving patient outcomes, expanding economic opportunities for its teammates, and strengthening community and environmental resilience. These new goals follow the company's successful achievement or exceeding of most of its previous five-year environmental, social, and governance (ESG) goals. The commitments address areas such as advancing patient care, driving economic mobility and teammate engagement, and strengthening community and environmental resilience, building on DaVita's strong track record and decades of progress in kidney care.
Zacks.com featured highlights include DaVita, Antero Resources, PBF Energy and Popular
This article identifies four low-PEG value stocks—DaVita (DVA), Antero Resources (AR), PBF Energy (PBF), and Popular (BPOP)—that are positioned for higher returns. It explains the importance of the PEG ratio in value investing to avoid "value traps" and highlights each company's strong fundamentals and growth prospects. The companies are presented as attractive investment opportunities based on their Zacks Rank and Value Score.
DaVita stock (US23918K1088): dialysis provider in focus after strong share price run
DaVita (US23918K1088) shares have recently surged, drawing investor attention to the U.S. dialysis specialist after a strong performance in 2025. The company's business model relies on providing essential kidney care services, largely reimbursed by government programs and private insurers, and is characterized by recurring revenue due to the chronic nature of kidney disease. DaVita's strategic focus includes expanding home dialysis options and maintaining cost efficiency within its extensive network of dialysis centers.
How Investors Are Reacting To DaVita (DVA) Q1 Earnings Beat And Aggressive Share Buybacks
DaVita Inc. (DVA) recently reported strong Q1 2026 results, with increased revenue and net income, alongside significant share repurchases totaling billions since 2020. This combination of better earnings per share and a reduced share count is positively influencing investor perception of the company's long-term financial health. While the core dialysis business is expected to generate steady cash flow, risks remain concerning treatment volumes and reimbursement policies.
DaVita stock (US23918K1088): shares stay near 2026 highs after latest pullback
DaVita Inc. shares have pulled back slightly but remain near their 2026 highs, reflecting strong year-to-date performance. The company, a major player in U.S. dialysis services, continues to draw investor attention due to its recurring revenue model and exposure to healthcare policy. Despite the recent rally, investors are now focused on whether the market can sustain its current valuation.
DaVita Inc. stock outperforms competitors on strong trading day
Shares of DaVita Inc. (DVA) rose 3.72% to $199.74 on Friday, outperforming the S&P 500 Index and Dow Jones Industrial Average, which both saw declines. This gain ended a two-day losing streak for the stock.
DaVita Inc. stock (US23918K1088): strong year-to-date rally despite latest pullback in healthcare sector
DaVita Inc. has seen a significant stock rally in 2026, gaining nearly 70% year-to-date despite a recent dip in healthcare stocks. The company, a major dialysis provider, benefits from non-discretionary demand driven by chronic illnesses, offering resilience across economic cycles. However, its performance is highly sensitive to reimbursement policies, payer mix, and regulatory changes, with recent rising short interest indicating market participants are hedging against potential risks.
DaVita Inc. stock underperforms Thursday when compared to competitors
Shares of DaVita Inc. (DVA) fell 2.79% on Thursday, closing at $192.58, despite a positive trading day for the broader stock market. The S&P 500 Index and Dow Jones Industrial Average both saw gains, making this DaVita's second consecutive day of losses.
DaVita CFO & Treasurer Joel Ackerman Sells 34% Of Holding
DaVita Inc.'s CFO & Treasurer, Joel Ackerman, recently sold 34% of his holdings in the company, netting approximately US$9.9 million. While a significant sale, the company's profitability and insider ownership of 2.2% suggest that this single transaction might not be a major cause for concern for investors. However, the article notes that insider selling at a price below the current valuation could raise questions about their perception of the stock's future.
DaVita stock (US23918K1088): TD Cowen raises price target after Q1 earnings
Following strong Q1 results, DaVita's shares are trading near 52-week highs, with a 6% revenue growth reported for fiscal year 2026. TD Cowen has increased its price target for DaVita to $201 from $144, while maintaining a Hold rating on the stock. DaVita's performance is tied to the US healthcare system and an aging population, making it relevant for investors in the sector despite recent insider stock sales.
Insider Sell Alert: David Maughan Sells 20,529 Shares of DaVita Inc (DVA)
David Maughan, COO of DaVita Kidney Care, sold 20,529 shares of DaVita Inc (DVA) on May 12, 2026, reducing his holdings to 94,105 shares. This sale is part of a trend of nine insider sells and no buys at the company over the past year. DaVita Inc, trading at $199.22 with a market cap of $12.715 billion, is considered modestly overvalued based on its GuruFocus Value of $171.68.
ARS Pharmaceuticals appoints Donn Casale as president
ARS Pharmaceuticals (NASDAQ: SPRY) has appointed Donn Casale as President, effective June 1, 2026, where he will oversee global commercial operations and growth infrastructure. Casale previously served as Chief Commercial Officer at Dynavax Technologies, significantly growing their hepatitis B vaccine, HEPLISAV-B. This appointment comes as ARS Pharmaceuticals prepares for expansion and continues to market neffy, an epinephrine nasal spray for severe allergic reactions.
What Does DaVita Inc.'s (NYSE:DVA) Share Price Indicate?
This article analyzes DaVita Inc.'s share price, suggesting it might be trading close to its fair value based on intrinsic valuation methods. While the stock appears reasonably priced, potential investors should consider future growth prospects and market risks. An upcoming dividend payment offers an additional income opportunity.
DaVita stock (US23918K1088): Q1 EPS beat and raised full-year guidance
DaVita reported strong Q1 results with an adjusted EPS of $2.87 and $140 million in free cash flow, exceeding expectations. The company also raised its full-year adjusted operating income guidance by $40 million and updated its adjusted EPS outlook, citing operational momentum in the dialysis services sector. DaVita holds a significant market share in the growing US dialysis market and continues to invest in integrated kidney care.
DaVita Inc. stock underperforms Wednesday when compared to competitors
Shares of DaVita Inc. (DVA) fell 1.22% on Wednesday, closing at $198.10, despite a mixed trading session for the broader market. This performance meant the stock underperformed compared to its competitors and broke a seven-day winning streak. The S&P 500 Index rose 0.58%, while the Dow Jones Industrial Average declined by 0.14%.
Baxter International Inc. stock (US0673431090): Recent 2% price gain on NYSE
Baxter International Inc. stock saw a 2.05% price gain on May 12, 2026, closing at $17.89 on the NYSE. The article highlights the company's core business in renal care and hospital products for the US market, noting its relevance for American investors. Despite industry pressures, Baxter maintains a competitive edge and continues to be tracked by investors for its role in healthcare.
DaVita stock (US23918K1088): Q1 EPS beat and raised full-year guidance
DaVita (US23918K1088) exceeded expectations in Q1 with an adjusted EPS of $2.87 and recorded $140 million in free cash flow. The company subsequently raised its full-year adjusted operating income guidance by $40 million and its adjusted EPS outlook to $14.10-$15.20 per share. This performance highlights the company's strong operational execution within the competitive US dialysis market.
Can AMN Healthcare Services Outrun CVS Health in the Next Rally?
This article analyzes whether AMN Healthcare Services (AMN) is a better investment than CVS Health (CVS) following a recent surge in CVS stock. It compares both companies on revenue growth, profitability, and valuation multiples, concluding that AMN offers superior fundamentals in several key areas. Despite this, the article also emphasizes the inherent risks in stock investment and suggests a portfolio approach for mitigating individual stock volatility.
DaVita Stock Rockets 32% With 7-Day Winning Streak
DaVita (DVA) stock experienced a 7-day winning streak, surging 32% and increasing its market cap by $3.3 billion to $14 billion. Despite this recent strong performance, Trefis rates the stock as "Risky" due to moderate operating performance and financial condition, even with a low valuation. The article emphasizes that focusing on predictive signals through platforms like Trefis's High Quality Portfolio is crucial for investors rather than reacting to news after it happens.
DaVita stock (US23918K1088): TD Cowen raises price target to $201
TD Cowen has raised its price target for DaVita Inc. (US23918K1088) from $144 to $201, following similar bullish revisions from other analysts like Deutsche Bank. This upgrade reflects increasing optimism for the kidney care provider, driven by its dominant market position in the US dialysis sector and a recession-resistant business model. The company's stock has shown strong recent momentum with significant gains, but ongoing insider sales and regulatory factors should be monitored by investors.
DaVita Stock 6-Day Winning Spree: Stock Climbs 31%
DaVita (DVA) stock has experienced a 6-day winning streak, increasing 31% and adding $3.2 billion to its market cap. Despite this surge, Trefis evaluates DVA as "Risky" due to a mix of moderate operating performance and financial condition, even with a low valuation. The article also provides a table comparing DVA's returns against the S&P 500 across various periods and lists key financial figures for the company.
Insider Sell: Joel Ackerman Sells 51,471 Shares of DaVita Inc (DVA)
Joel Ackerman, CFO and Treasurer of a DaVita Inc. subsidiary, sold 51,471 shares of DVA on May 7, 2026, reducing his holding to 132,434 shares. DaVita Inc. is currently considered modestly overvalued with a price-to-GF-Value ratio of 1.13, trading at $192.1 per share. This transaction is part of a trend of eight insider sells and no insider buys at DaVita over the past year.
Insider Sell: Joel Ackerman Sells 51,471 Shares of DaVita Inc (DVA)
Joel Ackerman, CFO and Treasurer of a DaVita Inc. subsidiary, sold 51,471 shares of DVA on May 7, 2026, reducing his holding to 132,434 shares. This transaction is part of a pattern over the last year where insiders have sold shares amounting to eight insider sells with no buys. DaVita Inc. is currently considered modestly overvalued with a price-to-GF-Value ratio of 1.13.
Fresenius Medical Care stock (DE0005785802): Latest developments in dialysis services
Fresenius Medical Care (FMC) reported stable performance in Q1 2026, with firm revenue in its core dialysis markets, driven by global demand for renal care services. The company, a leader in kidney care, focuses on vertically integrated dialysis products and services, particularly in North America, and is actively involved in home dialysis innovation and ESG initiatives. Despite regulatory pressures, FMC maintains a robust market position thanks to its extensive clinic network and strong US-centric earnings.
3,016 Shares in Western Digital Corporation $WDC Bought by Asahi Life Asset Management CO. LTD.
Asahi Life Asset Management CO. LTD. recently purchased 3,016 shares of Western Digital Corporation (NASDAQ:WDC) valued at approximately $520,000, establishing a new position in the company during the fourth quarter. Western Digital continues to attract significant institutional investment, with 92.51% of its stock held by institutions, and analysts remain bullish due to strong earnings and optimism surrounding AI-driven storage demand. The company also announced a dividend increase and progress in unwinding its Sandisk stake to become a more focused storage pure play.
DaVita Inc. stock (US23918K1088): Q1 2026 beat lifts shares after guidance hike
DaVita Inc. (DVA) saw its shares jump after beating Q1 2026 earnings estimates, raising its full-year guidance, and reporting strong cash flow, signaling durable performance in the kidney care sector. The company's revenue and diluted EPS surpassed analyst expectations, driven by resilient demand for dialysis services and solid operating execution. The stock's rally reflects strong investor confidence, though analysts maintain a "Hold" rating with an average 12-month price target that implies potential upside.
Fresenius Medical Care stock (DE0005785802): Dialysis giant faces headwinds and opportunities in 2026
Fresenius Medical Care reported mixed results for 2025, with revenue up but adjusted EBITDA and net income declining due to reimbursement pressures. The company issued a cautious outlook for 2026, expecting modest revenue growth and continued margin pressure, driven by stable dialysis volumes and ongoing reimbursement challenges in the U.S. FMC plans to focus on operational efficiency, expanding home-dialysis offerings, and investing in digital health tools to navigate the challenging market.
Fresenius Medical Care stock (DE0005785802): Dialysis giant faces pricing and reimbursement pressure
Fresenius Medical Care reported mixed first-quarter 2026 results, with modest revenue growth but continued pressure on profitability in its US dialysis business due to Medicare reimbursement dynamics and competitive pricing. Despite these challenges, the company maintained its full-year outlook, confident in underlying volume growth. For investors, the stock offers exposure to a global healthcare leader but carries policy-sensitive risks due to its dependence on government-set reimbursement rates in the US.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2026 Earnings Call Transcript
Akebia Therapeutics, Inc. reported its Q1 2026 earnings, with strong growth in Vafseo net product revenues, reaching $15.8 million, a 32% increase year-over-year, despite missing EPS expectations. The company highlighted increased prescriber engagement and patient adoption of Vafseo, driven by observed dosing protocols across dialysis organizations. Akebia also provided updates on its pipeline, including ongoing Phase II trials for praliciguat in FSGS and a planned Phase II trial for AKB-097, a novel complement inhibitor.
Fresenius Medical Care stock (DE0005785802): Dialysis giant faces pricing and reimbursement pressure
Fresenius Medical Care (FMC) reported mixed Q1 2026 results, with modest revenue growth but a decline in adjusted EBIT due to pricing pressures and reimbursement changes in key markets like the US and Europe. Despite these headwinds, the company maintained its full-year EBIT guidance, highlighting confidence in cost control and volume growth. FMC, the world's largest dialysis provider, faces challenges from rising operating costs and regulatory uncertainty but benefits from an aging population and increasing prevalence of chronic kidney disease.
DaVita Inc. stock (US23918K1088): Q1 2026 earnings and share buybacks lift sentiment
DaVita Inc. reported stronger-than-expected Q1 2026 results, with increased consolidated revenue, improved earnings per share, and robust cash flow. The company's share repurchase program further boosted investor sentiment. While the company's core business relies on dialysis services and is sensitive to reimbursement changes, its expansion into integrated kidney care and long-term demographic tailwinds offer potential for growth, requiring investors to balance cash flow strength against leverage and policy risks.
Insider Sell: James Hearty Sells Shares of DaVita Inc (DVA)
James Hearty, Chief Compliance Officer at DaVita Inc, sold 2,184 shares of DVA on May 6, 2026, bringing his total ownership to 35,953 shares. This sale follows a pattern of eight insider sells and no buys at DaVita Inc over the past year. The stock is currently trading at $174.87, indicating it is modestly overvalued with a price-to-GF-Value ratio of 1.03.
DaVita Inc. stock underperforms Friday when compared to competitors despite daily gains
DaVita Inc. (DVA) saw its stock advance 1.22% on Friday, closing at $198.65. Despite this daily gain and a favorable market session for the S&P 500 and Dow Jones, DaVita underperformed its competitors. This marks the stock's fifth consecutive day of gains.
DaVita Inc stock (US23804L1035): Shares surge after Q1 beat and guidance hike
DaVita Inc. (DVA) shares surged over 19% after the dialysis provider exceeded Q1 2026 earnings and revenue estimates and raised its full-year guidance. The company reported consolidated revenues of $3.42 billion and diluted EPS of $2.87, attributed to higher margins and operating rigor, alongside significant share repurchases. This performance highlights DaVita's strong position in the kidney-care segment, driven by stable demand and disciplined cost management, while also exposing investors to regulatory and reimbursement risks in the healthcare sector.
